ImagX is a multi-disciplinary team with competence in medical physics, signal processing, radiation oncology, and software development. The research environment provides a smooth connection between academic and industrial research. Links with IBA treatment centres ensure close contact with the clinical world. Aiming to develop advanced solution for image and dose guided proton therapy our research is directed along two main axes: (1) reduction of range uncertainties and (2) treatment of mobile tumours.
Proton therapy kills cancer cells by delivering proton beams to the tumour. Opposite to conventional radiation therapy, proton beams deposit their maximum energy within a precisely defined range, known as the Bragg peak. Owing to the finite range, the integral dose of a proton treatment is much lower than in conventional therapy. This results in better quality of life after treatment.
UCL and IBA are reinforcing their long-standing collaboration by founding a new research unit, called iMagX. The research unit is composed of the UCL’s IC-TEAM group on the Louvain-La-Neuve campus, the UCL’s MIRO group at the St Luc hospital in Brussels, and the research group of IBA. The collaboration successfully researched and engineered FDA approved in room imaging solutions that are now sold as products to IBA’s clients.
Company Details
- Founded
- 2011
- Address
- Chemin Du Cyclotron, 6, Louvain-La-Neuve,1348,belgium
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- imagx.org
- Keywords
- proton therapy, radiotherapy, R&D platform.
- HQ
- Louvain-la-Neuve
Imagx Questions
Imagx's website is imagx.org
Imagx's LinkedIn profile is https://be.linkedin.com/company/imagx
Imagx's industry is
Research Services
Imagx's categories are Research Services
Imagx's founding year is 2011
